GRAL
GRAIL, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$122.42
+3.91%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$2.50
- Revenue estimate
- $44.2M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$2.56
- EPS estimate
- -$2.66
- Revenue actual
- $44.7M
- Revenue estimate
- $42.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +18.6%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $135
- PT range
- $84 – $180
- Analysts
- 8
5 Buy3 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$2.66 | -$2.56 | Beat 3.76% | $44.7M |
| May 5, 2026 | -$2.76 | -$2.29 | Beat 17.11% | $40.8M |
| Feb 19, 2026 | -$3.33 | -$2.44 | Beat 26.73% | $43.6M |
| Nov 12, 2025 | -$3.36 | -$2.46 | Beat 26.79% | $36.2M |
| Aug 12, 2025 | -$3.14 | -$3.18 | Miss -1.27% | $35.5M |
| Feb 20, 2025 | -$4.41 | -$1.86 | Beat 57.82% | $38.3M |
| Mar 30, 2024 | — | -$7.05 | — | $26.7M |
| Dec 31, 2023 | — | -$0.18 | — | $30.3M |
| Sep 30, 2023 | — | -$29 | — | $20.7M |
| Apr 2, 2023 | — | -$6.24 | — | $19.6M |
| Sep 28, 2019 | — | -$0.49 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026